Several other research firms have also recently weighed in on FRE. Berenberg Bank set a €60.25 ($63.42) price objective on Fresenius SE & Co. KGaA in a report on Friday, April 29th. Credit Suisse Group set a €38.00 ($40.00) target price on Fresenius SE & Co. KGaA in a research note on Friday, May 6th. JPMorgan Chase & Co. set a €34.50 ($36.32) price target on Fresenius SE & Co. KGaA in a research note on Monday, April 11th. Jefferies Financial Group set a €40.00 ($42.11) target price on Fresenius SE & Co. KGaA in a research report on Thursday, March 31st. Finally, Sanford C. Bernstein set a €40.00 ($42.11) price target on Fresenius SE & Co. KGaA in a report on Thursday, March 3rd.
Shares of FRA:FRE opened at €34.09 ($35.88) on Tuesday. Fresenius SE & Co. KGaA has a twelve month low of €60.16 ($63.33) and a twelve month high of €80.00 ($84.21). The business has a fifty day moving average of €32.92 and a 200-day moving average of €35.00.
Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.